BioVex Garners $30,000,000 Series F Funding

  • Feed Type
  • Date
    11/10/2009
  • Company Name
    BioVex
  • Mailing Address
    34 Commerce Way Woburn, MA 01801
  • Company Description
    The Company is developing a new class of potent biologics for the treatment
    of cancer and prevention of infectious disease.
  • Website
    http://www.biovex.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series F
  • Proceeds Purposes
    The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
  • M&A Terms
  • Venture Investor
    Morningside Group
  • Venture Investor
    Ventech
  • Venture Investor
    MVM Life Science Partners
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.